Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
about
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaMedical treatment of renal cancer: new horizonsDo renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studiesThe ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer.KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Heart rate and its reduction in chronic heart failure and beyond.Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.Safety of available treatment options for renal cell carcinoma.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Renal cell carcinoma: new insights and challenges for a clinician scientist.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Renin angiotensin system deregulation as renal cancer risk factor.Individualized dosing with axitinib: rationale and practical guidance.Medication use and kidney cancer survival: A population-based study.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity
P2860
Q28066747-3B860FDE-B1A7-4F7C-8D3F-98EAF30B9EA6Q28073174-114359E6-ADE6-48FC-AD61-93783EF6652BQ30235047-AA55297C-5336-491B-9CFE-FEB200F9C043Q33645806-BB2554FA-D636-47F3-8BF0-4CF97078DE37Q36095196-1C9D7895-BA1F-496F-9635-F84DE9FE7D47Q36124825-B91333E1-65D9-48B2-BC7C-78FAD84FA0CDQ36600872-1B13D9CA-4A35-4531-B191-F6EE5D38A434Q36916329-15627D51-59A8-460F-B123-2C2086C42F24Q37461422-6B155F35-0ED0-43C8-97BF-CC342EF74D51Q38669556-CCD759A4-DEF0-4F07-8FD8-8FA2D1429E03Q38718044-15240C67-968A-401F-AA65-E10520352B09Q38824719-A27CC475-DAE8-4B80-97A8-4C30CF0C24E1Q39186183-2494CF05-0B99-4C68-AE66-B5E97C9AD9E1Q39222755-26C66DCD-F42E-44FC-8E9B-02A0A8439A5DQ41035635-CF6B3F19-E017-4A54-A0B2-32273B31743FQ41410574-9E19C760-1895-4271-AD72-B769AE4E2298Q42282790-7D3391C0-3808-4114-9172-FD13ECB9FCA6Q47094986-87F674DD-6990-4CC3-A75D-1739A6E8850DQ47271327-F01E1F6A-5CBD-4E6F-BB43-26DFBA1675A1Q47333254-37B9B524-2488-4D7E-9CB0-62527D55AE55Q47863448-F5AB1299-FAD7-4ED7-B7F5-1F249CA06CA1Q49568718-E60CEFF2-DA00-4AFE-9082-259758F8B0D1Q52808495-29F1D0AC-09C6-45C0-B032-5DC0B7390670Q59125636-8D7FB635-1DCF-4355-A4A9-7957BAB07AEA
P2860
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@ast
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@en
type
label
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@ast
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@en
prefLabel
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@ast
Angiotensin system inhibitors ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P1476
Angiotensin system inhibitors ...... etastatic renal cell carcinoma
@en
P2093
Gustavo E Rodriguez
Marina D Kaymakcalan
Rana R McKay
Rupal S Bhatt
Toni K Choueiri
Venkata S Sabbisetti
P2860
P304
P356
10.1158/1078-0432.CCR-14-2332
P407
P577
2015-02-27T00:00:00Z